William E. Delaney

6.8k total citations · 1 hit paper
125 papers, 5.1k citations indexed

About

William E. Delaney is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, William E. Delaney has authored 125 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Hepatology, 85 papers in Epidemiology and 42 papers in Infectious Diseases. Recurrent topics in William E. Delaney's work include Hepatitis C virus research (90 papers), Hepatitis B Virus Studies (83 papers) and HIV/AIDS drug development and treatment (34 papers). William E. Delaney is often cited by papers focused on Hepatitis C virus research (90 papers), Hepatitis B Virus Studies (83 papers) and HIV/AIDS drug development and treatment (34 papers). William E. Delaney collaborates with scholars based in United States, France and Australia. William E. Delaney's co-authors include Huiling Yang, Shelly Xiong, Craig S. Gibbs, Stephen Locarnini, Harriet C. Isom, Michael D. Miller, Patrick Marcellin, Carol Brosgart, Scott Bowden and Xiaoping Qi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and The Journal of Experimental Medicine.

In The Last Decade

William E. Delaney

122 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆

2004 733 citations William E. Delaney et al. Gastroenterology profile →

Peers

Countries citing papers authored by William E. Delaney

Since Specialization

Citations

This map shows the geographic impact of William E. Delaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Delaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Delaney more than expected).

Fields of papers citing papers by William E. Delaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William E. Delaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Delaney. The network helps show where William E. Delaney may publish in the future.

Co-authorship network of co-authors of William E. Delaney

This figure shows the co-authorship network connecting the top 25 collaborators of William E. Delaney. A scholar is included among the top collaborators of William E. Delaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William E. Delaney. William E. Delaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nomenclature of HBV core protein-targeting antivirals 2022 ·Nature Reviews Gastroenterology & Hepatology ·Fabien Zoulim, Adam Zlotnick, Stephanie Buchholz, Eric Donaldson, John Fry, Anuj Gaggar, Jianming Hu, Michael Kann, Oliver Lenz, Kai Lin, Nagraj Mani, Michael Nassal, William E. Delaney, Su Wang, Gabriel Westman, Veronica Miller, Harry L.A. Janssen	40
2	Establishment of infectious genotype 4 cell culture-derived hepatitis C virus 2019 ·Journal of General Virology ·Noriyuki Watanabe, (unknown), Tomoko Date, (unknown), (unknown), Hideki Aizaki, Masaya Sugiyama, Masashi Mizokami, William E. Delaney, Guofeng Cheng, Masamichi Muramatsu, Takaji Wakita	4
3	Anti-HBV activity of retinoid drugs in vitro versus in vivo 2019 ·Antiviral Research ·(unknown), (unknown), Robert Jordan, Tetsuya Kobayashi, Ryan A. Dick, (unknown), Li Li, Ricardo Ramírez, Madeleine Willkom, (unknown), William E. Delaney, Uli Schmitz	5
4	Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism 2017 ·Journal of Hepatology ·Congrong Niu, Li Li, Stéphane Daffis, Julie Lucifora, Marc Bonnin, (unknown), Eduardo Salas, (unknown), Hilario J. Ramos, Christine M. Livingston, Rudolf K. Beran, Abhishek V. Garg, Scott Balsitis, David Durantel, Fabien Zoulim, William E. Delaney, Simon P. Fletcher	71
5	A Whole Recombinant Yeast-Based Therapeutic Vaccine Elicits HBV X, S and Core Specific T Cells in Mice and Activates Human T Cells Recognizing Epitopes Linked to Viral Clearance 2014 ·PLoS ONE ·Thomas H. King, (unknown), Zhimin Guo, (unknown), Yingnian Lu, Claire Coeshott, Adam J. Gehring, Antonio Bertoletti, Zi Zong Ho, William E. Delaney, Anuj Gaggar, G. Mani Subramanian, John G. McHutchison, Shikha Shrivastava, Y.-J. Lee, Shyamasundaran Kottilil, Donald Bellgrau, Timothy C. Rodell, David Apelian	55
6	Hepatitis C Viral Entry Inhibitors Prolong Viral Suppression by Replication Inhibitors in Persistently-Infected Huh7 Cultures 2013 ·PLoS ONE ·(unknown), Andrew E. Greenstein, William E. Delaney, Rudolf K. Beran	6
7	Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors 2013 ·Antiviral Research ·(unknown), Margaret Robinson, Huiling Yang, (unknown), William E. Delaney	7
8	Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), T.C. Appleby, Thomas Butler, Ruby Cai, Xiaowu Chen, Aesop Cho, Michael O. Clarke, (unknown), William E. Delaney, Edward Doerffler, John O. Link, (unknown), Rowchanak Pakdaman, Hyung‐Jung Pyun, Qiaoyin Wu, Jie Xu, Choung U. Kim	26
9	Development of Robust Hepatitis C Virus Genotype 4 Subgenomic Replicons 2012 ·Gastroenterology ·Betty Peng, Yu Mei, Simin Xu, Yu‐Jen Lee, Tian Yang, Huiling Yang, (unknown), Hongmei Mo, John G. McHutchison, William E. Delaney, Guofeng Cheng	30
10	1198 NUCLEOTIDE INHIBITOR RESISTANCE SELECTIONS USING GT2A INFECTIOUS VIRUS: PSI-7851 AND GS-6620 SELECT FOR A NOVEL RESISTANCE PATHWAY INCLUDING SUBSTITUTIONS OF M289V/L FOLLOWED BY S282T 2011 ·Journal of Hepatology ·Genhong Cheng, Martijn Fenaux, Eric Mabery, (unknown), Betty Peng, Ona Barauskas, Leanna Lagpacan, Dong‐Yan Jin, Mien‐Chie Hung, (unknown), Julie Perry, Jie Feng, Adrian S. Ray, William E. Delaney, W Zhong	7
11	An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture 2011 ·Virology ·(unknown), Guofeng Cheng, Rudolf K. Beran, Huiling Yang, T.C. Appleby, Maria Pokrovskii, Hongmei Mo, Weidong Zhong, William E. Delaney	10
12	Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Anthony Casarez, Ruby Cai, Michael O. Clarke, Xiaowu Chen, Aesop Cho, William E. Delaney, Edward Doerffler, (unknown), Michael Mertzman, Rowchanak Pakdaman, Hyung‐Jung Pyun, (unknown), Qiaoyin Wu, Jie Xu, Choung U. Kim	28
13	Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus 2009 ·Antiviral Research ·Matthew Paulson, Huiling Yang, I‐hung Shih, Joy Y. Feng, Eric Mabery, Margaret Robinson, Weidong Zhong, William E. Delaney	18
14	Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates 2008 ·Antiviral Research ·Xiaoping Qi, Andrew Bae, Shan Liu, Huiling Yang, (unknown), Jeanette Harris, William E. Delaney, Michael D. Miller, Hongmei Mo	34
15	Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil 2007 ·Journal of Antimicrobial Chemotherapy ·William E. Delaney	28
16	Inhibitory Effect of Adefovir and Lamivudine on the Initiation of Hepatitis B Virus Infection in Primary Tupaia Hepatocytes 2003 ·Hepatology ·Josef Köck, Thomas F. Baumert, William E. Delaney, Hubert E. Blum, Fritz von Weizsäcker	58
17	Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks 2002 ·Hepatology ·Huiling Yang, Christopher Westland, William E. Delaney, E. Jenny Heathcote, Victoria Ho, John Fry, Carol Brosgart, Craig S. Gibbs, Michael D. Miller, Shelly Xiong	132
18	Synthesis and Properties of Oligonucleotide (2-Aminoethyl)Phosphonates 1995 ·Nucleosides and Nucleotides ·Alan F. Cook, Reza Fathi, Qing Huang, (unknown), William E. Delaney, (unknown)	2
19	Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates 1994 ·Nucleic Acids Research ·Reza Fathi, Qing Huang, (unknown), William E. Delaney, Rebecca M. Teasdale, Arthur Μ. Krieg, Alan F. Cook	42
20	Neonatal omphalitis and pyelonephritis 1959 ·The Journal of Pediatrics ·William E. Delaney	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact